Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.

Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion.
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells.
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells.
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Kumar D, et al. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 2015 Dec;141(12):1133-9.  [Content Brief]